Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/359708
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-02-02T10:37:41Z-
dc.date.available2022-02-02T10:37:41Z-
dc.identifier.urihttp://hdl.handle.net/10603/359708-
dc.description.abstractBrimonidine tartrate (BRT) is a hydrophilic anti-glaucoma medicine available in solution form (Brimopress Eye Drops) in the market. The improved PCL/PLGA and vitamin E TPGS based regulations were studied and evaluated. BRT-PLGA NPs were formulated, and it was observed that the size of NPs was in the range. Surface morphology studies and DSC revealed that BRT-PLGA NPs exhibited a smooth and spherical morphology. From these findings, it can be said that the thermo responsiveness of poloxamer gel is considerably relied on concentration. Higher amount of poloxamer 407 leads to rapid gelation, but at lower gelation temperature. Results showed that gels exhibit greater network and showed rigidity at fixed Poloxamer concentration. In case of BRT-PLGA-NPs loaded carbopol/HPMC based in situ gelling system all formulations were clear and colorless but little translucent due to the opalescent nature of nanodispersion. The highest cumulative release rate of the drug in simulated aqueous humour over 24 h was confirmed in an in vitro evaluation. The developed in situ gel showed a higher ix permeation rate through the goat eye 51.18 ;g.cm-2 .h-1 (PCL NPs) and 50.24 ;g.cm 2 .h-1 (PLGA NPs) in 4 h whereas, marketed eye drop showed 7.618 ;g.cm-2 .h-1 and BRT in situ gel showed 20.56 ;g.cm-2 .h-1 transcorneal flux in 4 h. In addition, novel optimized in situ gel showed sustained action and continuously reduction of IOP till 12 h. The optimized preparation also studied for in vivo ocular irritability and tolerability indicates no signs of discomfort. In vivo ocular irritancy test was performed in the rabbit eye to check the dose related hyperaemia of BRT. Slight redness has been observed in rabbit eyes with not only the marketed eye drop but also finally optimized formulation of BRT (0.1% w/v). Therefore, the reduced concentration of BRT i.e.0.05% and 0.025% was prepared using previously optimized formula. Percent reduction of IOP of 0.05% and 0.025% of BRT NPs based in situ gel showed 34.377;4.21% and 13.61;3.01%-
dc.format.extentIX, 144p.-
dc.languageEnglish-
dc.rightsuniversity-
dc.titleDevelopment and Evaluation of Ophthalmic Drug Delivery System for Glaucoma-
dc.creator.researcherSharma, Pankaj Kumar-
dc.subject.keywordAnti-glaucoma medicine-
dc.subject.keywordBrimonidine tartrate-
dc.subject.keywordClinical Pre Clinical and Health-
dc.subject.keywordOphthalmic Drug Delivery System-
dc.subject.keywordPharmacology and Pharmacy-
dc.subject.keywordPharmacology and Toxicology-
dc.contributor.guideChauhan, Meenakshi Kanwar-
dc.publisher.placeNew Delhi-
dc.publisher.universityDelhi Pharmaceutical Sciences and Research University (DPSRU)-
dc.publisher.institutionPharmaceutics-
dc.date.registered2016-
dc.date.completed2022-
dc.format.accompanyingmaterialCD-
dc.source.universityUniversity-
dc.type.degreePh.D.-
Appears in Departments:Pharmaceutics

Files in This Item:
File Description SizeFormat 
01_title page.pdfAttached File35.48 kBAdobe PDFView/Open
02_certificate.pdf755.47 kBAdobe PDFView/Open
03_preliminary pages.pdf2.3 MBAdobe PDFView/Open
04_chapter 1.pdf638.65 kBAdobe PDFView/Open
05_chapter 2.pdf235.24 kBAdobe PDFView/Open
06_chapter 3.pdf695.43 kBAdobe PDFView/Open
07_chapter 4.pdf1.53 MBAdobe PDFView/Open
08_chapter 5.pdf2.59 MBAdobe PDFView/Open
09_chapter 6.pdf188.08 kBAdobe PDFView/Open
10_bibliography.pdf355.47 kBAdobe PDFView/Open
11_appendix.pdf2.68 MBAdobe PDFView/Open
80_recommendation.pdf264.94 kBAdobe PDFView/Open
abstract.pdf10.12 kBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: